Sponsors are encouraged about prospects for FDA approval of the first drugs for female sexual desire disorders following a pair of meetings with patients and clinician experts, despite a backlash against industry involvement in the process.
From Oct
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?